Tumor cell vascular mimicry: Novel targeting opportunity in melanoma

Mary J.C. Hendrix*, Elisabeth A. Seftor, Richard E.B. Seftor, Jun Tzu Chao, Du Shieng Chien, Yi Wen Chu

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

120 Scopus citations


In 1999, the American Journal of Pathology published an article, entitled "Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry" by Maniotis and colleagues, which ignited a spirited debate for several years and earned the journal's distinction of a "citation classic" (Maniotis et al., 1999). Tumor cell vasculogenic mimicry (VM), also known as vascular mimicry, describes the plasticity of aggressive cancer cells forming de novo vascular networks and is associated with the malignant phenotype and poor clinical outcome. The tumor cells capable of VM share the commonality of a stem cell-like, transendothelial phenotype, which may be induced by hypoxia. Since its introduction as a novel paradigm for melanoma tumor perfusion, many studies have contributed new findings illuminating the underlying molecular pathways supporting VM in a variety of tumors, including carcinomas, sarcomas, glioblastomas, astrocytomas, and melanomas. Of special significance is the lack of effectiveness of angiogenesis inhibitors on tumor cell VM, suggesting a selective resistance by this phenotype to conventional therapy. Facilitating the functional plasticity of tumor cell VM are key proteins associated with vascular, stem cell, extracellular matrix, and hypoxia-related signaling pathways - each deserving serious consideration as potential therapeutic targets and diagnostic indicators of the aggressive, metastatic phenotype. This review highlights seminal findings pertinent to VM, including the effects of a novel, small molecular compound, CVM-1118, currently under clinical development to target VM, and illuminates important molecular pathways involved in the suppression of this plastic, aggressive phenotype, using melanoma as a model.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalPharmacology and Therapeutics
StatePublished - Mar 1 2016


  • CVM-1118
  • Melanoma
  • Transendothelial phenotype
  • Tumor cell plasticity
  • Vascular mimicry
  • Vascular mimicry pathways

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Tumor cell vascular mimicry: Novel targeting opportunity in melanoma'. Together they form a unique fingerprint.

Cite this